This content is first seen at HSA website.
Disclaimer: The information provided in this site is correct at the time of publication. POMConnect assumes no responsibility or liability for any errors or omissions in the content of this site.
HSA Safety Alert: Withdrawal Of Pholcodine-Containing Products In Singapore
The Health Sciences Authority (HSA) aims to notify medical practitioners about its regulatory choice to remove products containing pholcodine from circulation in Singapore. After conducting a benefit-risk evaluation, HSA, in consultation with its Product Vigilance Advisory Committee (PVAC), has determined that the advantages of using pholcodine for alleviating non-productive cough symptoms are outweighed by the potential elevated risk of perioperative anaphylaxis (POA) associated with neuromuscular blocking agents (NMBA).
Read More Link to the full announcement:
https://www.pom.com.sg/var/images/POMConnect/WithdrawalofpholcodinecontainingproductsinSingapore_HSA-17-2023_1.pdf?_t=1687488799
If you encounter customers feedback of adverse events relating to use of the product, please report to HSA: https://www.hsa.gov.sg/adverse-events
